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Abstract 
The COVID-19 vaccines comprised of adenoviral vectors encoding the Spike (S) glycoprotein of SARS-CoV-2 are 
highly effective but associated with rare thrombotic complications. The adenovirus vector infects epithelial cells 
expressing the coxsackievirus and adenovirus receptor (CAR). The S glycoprotein expressed locally stimulates 
neutralizing antibody and cellular immune responses. These vaccines have been associated with thromboem-
bolic events including cerebral venous sinus thrombosis (CVST). S glycoprotein stimulates the expression of cy-
clooxygenase-2 (COX-2) and leads to massive generation of thromboxane A2 in COVID-19. Megakaryocytes ex-
press CAR and we postulate that S glycoprotein stimulated generation of thromboxane A2 leads to megakaryo-
cyte activation, biogenesis of activated platelets and thereby increased thrombogenicity. Cerebral vein sinuses 
express podoplanin, a natural ligand for CLEC2 receptors on platelets. Platelets traversing through the cerebral 
vein sinuses could be further activated by thromboxane A2-dependent podoplanin-CLEC2 signaling, leading to 
CVST. A prothrombotic hormonal milieu, and increased generation of thromboxane A2 and platelet activation in 
healthy females compared to males is consistent with increased risk for CVST observed in women. We propose 
that antiplatelet agents targeting thromboxane A2 receptor signaling such as low-dose aspirin merit considera-
tion for chemoprophylaxis when administering the adenovirus based COVID-19 vaccines to young adults at risk 
of thrombosis provided there are no contraindications. 
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TxA2 - thromboxane A2, DIC - disseminated in-
travascular coagulopathy, COX - cyclooxygenase, 
TTP - thrombotic thrombocytopenic purpura, CVST - 
cerebral venous sinus thrombosis, CLEC - C-type lec-
tin-like receptor - TLR, toll-like receptor, CAR - cox-
sackievirus and adenovirus receptor, COVID-19 - 
coronavirus disease 2019, SARS-CoV-2 - severe 
acute respiratory syndrome coronavirus 2, PF4 - 
platelet factor 4 
Introduction 
COVID-19 disease is caused by a novel positive-
strand RNA coronavirus (SARS-CoV-2), which be-
longs to the Coronaviridae family, along with the se-
vere acute respiratory syndrome (SARS) and the 
Middle East respiratory syndrome (MERS) corona-
viruses.1 The genome of these viruses encodes sev-
eral non-structural and structural proteins, including 
spike, envelope, membrane, and nucleocapsid pro-
teins.2 The majority of the vaccines for COVID-19 
that employ administration of viral antigens or viral 
gene sequences aim to induce neutralizing antibod-
ies against the viral spike protein (S), preventing up-
take through the ACE2 receptor, and thereby block-
ing infection.3 
The Janssen COVID-19 vaccine (Johnson & 
Johnson) is comprised of a recombinant, replication- 
incompetent Ad26 vector, encoding a stabilized var-
iant of the SARS-CoV-2 spike protein. The ChAdOx1 
nCoV-19 vaccine (AZD1222, Vaxzevria®) was devel-
oped at Oxford University and consists of a replica-
tion-deficient chimpanzee adenoviral vector ChA-
dOx1, encoding the S protein.4 In US Phase III trials, 
Vaxzevria has been demonstrated to have 79% effi-
cacy at preventing symptomatic COVID-19, and 
100% efficacy against severe or critical disease and 
hospitalization, with comparable efficacy across eth-
nicity, gender and age.5 However, Vaxzevria has 
been associated with thrombotic and embolic 
events including disseminated intravascular coagu-
lation (DIC) and cerebral venous sinus thrombosis 
(CVST), occurring within 14 days after vaccination, 
mostly in people under 55 years of age, the majority 
of whom have been women.6 Data from Europe sug-
gests that the event rate for thromboembolic events
may be about 10 per million vaccinated. Antibodies 
to platelet factor 4 (PF4)/heparin complexes have 
been recently reported in a few patients.7 However, 
the significance of this finding remains to be estab-
lished. As of April 12, 2021, about 6.8 million doses 
of the Janssen vaccine have been administered in 
the U.S.8 CDC and FDA are reviewing data involving 
six reported U.S. cases of CVST in combination with 
thrombocytopenia.8 All six cases occurred among 
women between the ages of 18 and 48, and symp-
toms occurred 6 to 13 days after vaccination.8 
SARS-CoV-2 is known to cause thromboinflam-
mation leading to thrombotic microangiopathy, pul-
monary thrombosis, pedal acro-ischemia (“COVID-
toes”), arterial clots, strokes, cardiomyopathy, coro-
nary and systemic vasculitis, deep venous throm-
bosis, pulmonary embolism, and microvascular 
thrombosis in renal, cardiac and brain vascular-
ture.9-14 Cerebral venous sinus thrombosis (CVST) 
has also been reported in COVID-19 patients.15 
Amongst 34,331 hospitalized COVID-19 patients, 
CVST was diagnosed in 28.16 In a multicenter, multi-
national, cross sectional, retrospective study of 8 pa-
tients diagnosed with CVST and COVID-19, seven 
were women with an average age of 63 years.17 In a 
combined series of 41 patients with COVID-19 and 
CVST, the average age was about 50 years (SD, 16.5 
years).17 The pathobiology of thrombotic events as-
sociated with the AstraZeneca vaccine should be 
viewed in the context of mechanisms underlying 
thromboinflammation that complicates SARS-CoV-2 
infection and COVID-19 disease. 
A. Role of COX-2 and thromboxane A2 
in thromboinflammation complicating 
adenovirus-based COVID-19 vaccine 
encoding the Spike protein of SARS-
CoV-2 
Thromboinflammation in COVID-19 seems to 
be primarily caused by endothelial, platelet and neu-
trophil activation, platelet-neutrophil aggregates 
and release of neutrophil extracellular traps 
(NETs).13,18 Platelet activation in COVID-19 is fueled 
by a lipid storm characterized by massive increases 
in thromboxane A2 (TxA2) levels in the blood and 
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bronchoalveolar lavage fluid.19,20 Cyclooxygenase 
(COX) enzymes catalyze the first step in the biosyn-
thesis of thromboxane A2 from arachidonic acid, and 
COX-2 expression is induced by the spike protein of 
coronaviruses.21 We postulate that an aberrant in-
crease in thromboxane A2 generation induced by the 
spike protein expression from adenovirus vaccines 
leads to thromboinflammation and CVST. 
The support for the above proposed mecha-
nism comes from the following observations. First, 
when mice of different age groups were infected 
with SARS-CoV virus, the generation of TxA2 was 
markedly increased in younger mice compared to 
middle aged mice.22 Furthermore, in children with 
asymptomatic or mildly symptomatic SARS-CoV-2 
infection, microvascular thrombosis and thrombotic 
microangiopathy occur early in infection.19 These 
observations are consistent with the higher risk for 
thrombosis in adults under 60 years of age, com-
pared with the older age group.6,7 Second, platelets 
from female mice are much more reactive than from 
male mice.23 Furthermore, TxA2 generation, TxA2-
platelet interaction and platelet activation is in-
creased in women compared to men.24,25 These ob-
servations are consistent with disproportionately in-
creased risk of thrombosis in women following 
AstraZeneca and Janssen COVID-19 vaccines. 
The adenoviral vector ChAdOx1, containing the 
nCoV-19 spike protein gene, infects host cells 
through the coxsackievirus and adenovirus receptor 
(CAR).26 CAR-dependent cell entry of the viral vector 
allows insertion of the SARS-CoV-2 spike protein 
gene and expression of spike protein by host cells 
(Figure 1). CAR is primarily expressed on epithelial 
tight junctions including on enterocytes.27,28 CAR ex-
pression has also been reported in platelets,29 and, 
since platelets are anucleate cells, CAR expression 
by megakaryocytes can be inferred. Therefore, 
AstraZeneca and Janssen vaccines would be ex-
pected to induce expression of spike protein in 
megakaryocytes, platelets (Figure 1) and entero-
cytes. We postulate that the expression of CAR re-
ceptors by basolateral membrane on enterocytes al-
lows uptake of adenovirus vector,28 leading to spike 
protein-induced COX-2 expression and generation 
of thromboxane A2. Delivery of thromboxane A2 into 
the splanchnic circulation could activate platelets lo-
cally, leading to splanchnic vein thrombosis associ-
ated with adenovirus vaccines.30 
Spike protein of coronaviruses is known to in-
duce COX-2 gene expression.21,31 COX-2 expression is 
induced during normal human megakaryopoiesis 
and characterizes newly formed platelets.32 While in 
healthy controls <10% of circulating platelets ex-
press COX-2, in patients with high platelet genera-
tion, up to 60% of platelets express COX-2.32 Gener-
ation of TxA2 by platelets is markedly suppressed by 
COX-2 inhibition in patients with increased megakar-
yopoiesis versus healthy subjects.32 Therefore, we 
postulate that expression of spike protein induces 
COX-2 expression and generation of thromboxane 
A2 by megakaryocytes. TxA2 promotes biogenesis of 
activated platelets expressing COX-2. Platelet TxA2 
generation leads to platelet activation and aggrega-
tion, and thereby thromboinflammation (Figure 1). 
Extravascular spaces of the lungs comprise 
populations of mature and immature megakaryo-
cytes that originate from the bone marrow, such 
that lungs are a major site of platelet biogenesis, ac-
counting for approximately 50% of total platelet 
production or about 10 million platelets per hour.33 
More than 1 million extravascular megakaryocytes 
have been observed in each lung of transplant 
mice.33 Following intramuscular injection of the 
AstraZeneca and Janssen vaccines, the adenovirus 
vector will traverse the veins and lymphatics to be 
delivered to the pulmonary circulation, thereby ex-
posing lung megakaryocytes in the first pass. Inter-
estingly, under thrombocytopenic conditions, 
haematopoietic progenitors migrate out of the lung 
to repopulate the bone marrow and completely re-
constitute blood platelet count.33 Since thrombocy-
topenia is a common feature of CVST associated 
with adenovirus SARS-CoV-2 vaccines, migration of 
megakaryocytes from the lungs into the systemic 
circulation including the cerebral circulation could 
further predispose to CVST. In this regard, it is rele-
vant that megakaryocytes have been found in the 
cerebral circulation in patients deceased from se-
vere COVID-19.34 
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Figure 1. AstraZeneca or Janssen COVID-19 vaccine-induced thromboinflammation and cerebral venous sinus thrombosis (CVST) - Pro-
posed Mechanisms: Adenovirus carrier delivers SARS-CoV-2 DNA encoding the spike (S) protein to the lung megakaryocytes via the cox-
sackie-adenovirus receptor (CAR). Spike protein induces COX-2 expression in megakaryocytes leading to megakaryocyte activation, bio-
genesis of activated platelets that express COX-2 and generate thromboxane A2 (TxA2). Cerebral venous sinuses express podoplanin, a 
natural ligand for CLEC2 receptors on platelets. Platelets traversing through the cerebral venous sinuses would be further activated by 
thromboxane A2-dependent podoplanin-CLEC2 signaling, leading to release of extracellular vesicles, thereby promoting CLEC5A- and TLR2-
mediated neutrophil activation, thromboinflammation and CVST. Young age and female gender are associated with increased TxA2 gen-
eration and platelet activation, respectively, and hence increased risk of thromboembolic complications following SARS-CoV-2 vaccination 
with adenovirus-based vaccines. 
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The prothrombotic mechanisms postulated 
above could be operative alone or in conjunction 
with other underlying factors that have been pro-
posed including the presence of anti-platelet factor 
4 (PF4) antibodies as reported by Greinacher and 
others.7 Notably, amongst 31 cases of CVST in close 
temporal relationship with a COVID-19 vaccination, 
anti-PF4 antibodies were positive in 22 cases and 
negative in 9.35 Therefore, CVST following COVID-19 
vaccination appears to be a multifactorial disease. 
Further studies using cultured megakaryocytes and 
animal models are needed to define the underlying 
mechanisms. Even though the risk of CVST is in-
creased about 10-fold by the adenovirus based 
COVID-19 vaccines,36 it remains unclear why CVST 
remains a rare event. To further define the im-
portance of these causative factors, biomarkers 
such as plasma thromboxane B2, anti-PF4 antibodies 
and anti-phospholipid antibodies should be meas-
ured in the thrombosis-free vaccinated population. 
Such studies may help define the role of anti-PF4 an-
tibodies as causative versus an epiphenomenon. 
Interestingly, almost all patients with throm-
bosis and thrombocytopenia were found to have 
anti-PF4 antibodies.35 On the other hand, majority of 
patients with thrombosis without thrombocytope-
nia lacked anti-PF4 antibodies.35 The postulated 
mechanisms may be especially relevant to throm-
botic events occurring in the absence of thrombocy-
topenia or anti-PF4 antibodies. 
B. Predilection of cerebral venous si-
nuses for thrombosis following vac-
cination 
Recent studies have demonstrated that arte-
rial, venous and sinusoidal endothelial cells in the 
brain uniquely express markers of the lymphatic en-
dothelium including podoplanin.37 Podoplanin (D2-
40) serves as a ligand for CLEC2 receptors on plate-
lets.38 Thromboxane A2-dependent CLEC2 signaling 
leads to platelet activation (Figure 1), while a TxA2 
receptor antagonist nearly abolished CLEC2 signal-
ing and platelet activation.38 TxA2-dependent CLEC2 
signaling promotes release of exosomes and mi-
crovesicles from platelets, leading to activation of 
CLEC5A and TLR2 receptors respectively on neutro-
phils, neutrophil activation and release of neutrophil 
extracellular traps (NETs) (Figure 1).39 Neutrophil ac-
tivation, more than platelet activation, is associated 
with thrombotic complications in COVID-19.13,18,40 As 
proposed above, the expression of podoplanin by 
cerebral venous sinuses may be responsible for the 
predilection of brain vascular bed to thromboinflam-
mation and CVST as a complication of COVID-19 vac-
cines. The valves at the lymphovenous junction and 
the podoplanin-CLEC2 lymphovenous hemostasis 
act as “fail-safe” mechanisms to prevent movement 
of blood into the lymphatic system, thereby pre-
venting coagulation in the lymphatics despite ex-
pression of podoplanin in the lymphatic endothe-
lium.41 
C. Chemoprophylaxis with antiplatelet 
agents 
In animal models of endotoxin-mediated endo-
thelial injury and thromboinflammation, antago-
nism of thromboxane A2 signaling prevents ARDS, 
reduces myocardial damage and increases sur-
vival.42-44  
Considering the key role played by platelets in 
thromboinflammation, we propose consideration of 
anti-platelet agents, either aspirin or TxA2 receptor 
antagonists, as chemoprophylactic agents when the 
AstraZeneca vaccine is administered to adults be-
tween 18 and 60 years of age.45 High bleeding risk 
because of another medical condition or medication 
would be contraindications to use of antiplatelet 
agents.45 Medical conditions that increase bleeding 
risk include previous gastrointestinal bleeding, pep-
tic ulcer disease, blood clotting problems, and kid-
ney disease.45 Medications that increase bleeding 
risk include nonsteroidal anti-inflammatory drugs, 
steroids, and other anticoagulants or anti-platelet 
agents.45 Aspirin appears to be safe in COVID-19. In 
a retrospective observational study in hospitalized 
patients with COVID-19, low-dose aspirin was found 
to be effective in reducing morbidity and mortality 
and was not associated with any safety issues includ-
ing major bleeding.46 Therefore, aspirin is likely to be 
safe as an adjunct to COVID-19 vaccines even in the 
event of a subsequent infection with SARS-CoV-2 vi-
rus. 
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Can aspirin influence the host immune re-
sponse to the COVID-19 vaccines? This issue merits 
further investigation. When healthy adults > 65 
years of age were given influenza vaccine and ran-
domized to receive 300 mg aspirin or placebo on 
days 1, 2, 3, 5 and 7, the aspirin group showed 4-fold 
or greater rise in influenza specific antibodies.47 The 
risk-benefit analysis, based on above information, 
suggests that a one to three week course of low-
dose aspirin merits consideration in order to prevent 
the thromboembolic events associated with the 
AstraZeneca vaccine. 
Summary 
Thromboembolic disease, CVST and thrombo-
cytopenia have been reported in association with 
AstraZeneca and Janssen COVID-19 vaccines, espe-
cially in younger women. Many countries have 
halted use of these vaccines for adults under 30 to 
60 years of age. European and North American 
countries generally have access to mRNA vaccines. 
However, in many Asian and African countries the 
choices are limited to adenovirus-based COVID-19 
vaccines. The governments in such countries are 
forging ahead with vaccinating all adults, including 
those under 60 years of age, with Vaxzevria, Cov-
ishield (the version of Vaxzevria manufactured by 
the Serum Institute of India) or the Janssen vaccines. 
This has led to grave concern and anxiety amongst 
the citizens and medical professionals. Considering 
the profound global public health implications of 
limiting the use of these vaccines, it is critical to un-
derstand the pathobiology of vaccination induced 
thrombotic events in order to guide strategies 
aimed at prevention. In this regard, studies are ur- 
 
gently needed to examine lipid mediators and the 
thromboxane A2 - platelet axis following vaccination 
with these vaccines compared with mRNA vaccines. 
The risk-benefit analysis based on information pre-
sented here suggests that chemoprophylaxis using a 
short course of low-dose aspirin in adults under 60 
years of age and lacking any contraindications to as-
pirin may be justified in conjunction with adenovi-
rus-based COVID-19 vaccines in order to prevent 
thromboembolic events and enhance safety. 
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